This company is no longer active
IMARA Balance Sheet Health
Financial Health criteria checks 6/6
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$88.20m |
| Equity | US$90.13m |
| Total liabilities | US$1.83m |
| Total assets | US$91.96m |
Recent financial health updates
We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Jul 23
We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Sep 09Is IMARA (NASDAQ:IMRA) In A Good Position To Invest In Growth?
May 03Companies Like IMARA (NASDAQ:IMRA) Are In A Position To Invest In Growth
Jan 11Recent updates
Cancer drug developer Enliven Therapeutics and Imara to merge in all-stock deal
Oct 13Imara: Potential Liquidation
Sep 29We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Jul 23We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Sep 09IMARA (IMRA) EHA Investor Presentations - Slideshow
Jun 18Is IMARA (NASDAQ:IMRA) In A Good Position To Invest In Growth?
May 03Companies Like IMARA (NASDAQ:IMRA) Are In A Position To Invest In Growth
Jan 11Imara's sickle cell treatment shows promising action in mid-stage study
Jan 06Imara EPS in-line
Nov 05Financial Position Analysis
Short Term Liabilities: IMRA's short term assets ($89.6M) exceed its short term liabilities ($1.8M).
Long Term Liabilities: IMRA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IMRA is debt free.
Reducing Debt: IMRA has no debt compared to 5 years ago when its debt to equity ratio was 7.6%.
Debt Coverage: IMRA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: IMRA has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/24 08:00 |
| End of Day Share Price | 2023/02/23 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IMARA Inc. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Edward White | H.C. Wainwright & Co. |
| Joseph Schwartz | Leerink Partners LLC |